Cargando…

Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma

BACKGROUND: Allergic rhinitis (AR) and allergic asthma are caused by an IgE-mediated inflammatory reaction. Probiotics may exert anti-inflammatory and immune-modulatory activity. Thus, this study aimed at investigating whether a Bifidobacteria mixture could be able to relieve nasal symptoms, and aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Giudice, Michele Miraglia, Indolfi, Cristiana, Capasso, Michele, Maiello, Nunzia, Decimo, Fabio, Ciprandi, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341466/
https://www.ncbi.nlm.nih.gov/pubmed/28270216
http://dx.doi.org/10.1186/s13052-017-0340-5
_version_ 1782512996795285504
author Del Giudice, Michele Miraglia
Indolfi, Cristiana
Capasso, Michele
Maiello, Nunzia
Decimo, Fabio
Ciprandi, Giorgio
author_facet Del Giudice, Michele Miraglia
Indolfi, Cristiana
Capasso, Michele
Maiello, Nunzia
Decimo, Fabio
Ciprandi, Giorgio
author_sort Del Giudice, Michele Miraglia
collection PubMed
description BACKGROUND: Allergic rhinitis (AR) and allergic asthma are caused by an IgE-mediated inflammatory reaction. Probiotics may exert anti-inflammatory and immune-modulatory activity. Thus, this study aimed at investigating whether a Bifidobacteria mixture could be able to relieve nasal symptoms, and affect quality of life (QoL) in children with AR and intermittent asthma due to Parietaria allergy. MATERIALS AND METHODS: The present study was conducted as placebo-controlled, double-blinded, and randomized. Globally, 40 children (18 males; mean age 9 ± 2.2 years) were enrolled. They were treated with probiotics or placebo: 1 sachet/day for 4 weeks. AR symptoms, and QoL were assessed at baseline and after treatment. Use of rescue medications, such as cetirizine syrup and salbutamol spray, was also permitted and recorded. RESULTS: Children treated with probiotic mixture achieved a significant improvement of symptoms (p < 0.005), and QoL ((p < 0.001). Placebo group had worsening of symptoms (p < 0.005) and QoL (p < 0.001). The use of rescue medications was overlapping in the two groups. The intergroup analysis showed that probiotic mixture was significantly superior than placebo for all parameters. CONCLUSIONS: The current study demonstrated that a Bifidobacteria mixture was able of significantly improving AR symptoms and QoL in children with pollen-induced AR and intermittent asthma. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT02807064.
format Online
Article
Text
id pubmed-5341466
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53414662017-03-10 Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma Del Giudice, Michele Miraglia Indolfi, Cristiana Capasso, Michele Maiello, Nunzia Decimo, Fabio Ciprandi, Giorgio Ital J Pediatr Research BACKGROUND: Allergic rhinitis (AR) and allergic asthma are caused by an IgE-mediated inflammatory reaction. Probiotics may exert anti-inflammatory and immune-modulatory activity. Thus, this study aimed at investigating whether a Bifidobacteria mixture could be able to relieve nasal symptoms, and affect quality of life (QoL) in children with AR and intermittent asthma due to Parietaria allergy. MATERIALS AND METHODS: The present study was conducted as placebo-controlled, double-blinded, and randomized. Globally, 40 children (18 males; mean age 9 ± 2.2 years) were enrolled. They were treated with probiotics or placebo: 1 sachet/day for 4 weeks. AR symptoms, and QoL were assessed at baseline and after treatment. Use of rescue medications, such as cetirizine syrup and salbutamol spray, was also permitted and recorded. RESULTS: Children treated with probiotic mixture achieved a significant improvement of symptoms (p < 0.005), and QoL ((p < 0.001). Placebo group had worsening of symptoms (p < 0.005) and QoL (p < 0.001). The use of rescue medications was overlapping in the two groups. The intergroup analysis showed that probiotic mixture was significantly superior than placebo for all parameters. CONCLUSIONS: The current study demonstrated that a Bifidobacteria mixture was able of significantly improving AR symptoms and QoL in children with pollen-induced AR and intermittent asthma. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT02807064. BioMed Central 2017-03-07 /pmc/articles/PMC5341466/ /pubmed/28270216 http://dx.doi.org/10.1186/s13052-017-0340-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Del Giudice, Michele Miraglia
Indolfi, Cristiana
Capasso, Michele
Maiello, Nunzia
Decimo, Fabio
Ciprandi, Giorgio
Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma
title Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma
title_full Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma
title_fullStr Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma
title_full_unstemmed Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma
title_short Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma
title_sort bifidobacterium mixture (b longum bb536, b infantis m-63, b breve m-16v) treatment in children with seasonal allergic rhinitis and intermittent asthma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341466/
https://www.ncbi.nlm.nih.gov/pubmed/28270216
http://dx.doi.org/10.1186/s13052-017-0340-5
work_keys_str_mv AT delgiudicemichelemiraglia bifidobacteriummixtureblongumbb536binfantism63bbrevem16vtreatmentinchildrenwithseasonalallergicrhinitisandintermittentasthma
AT indolficristiana bifidobacteriummixtureblongumbb536binfantism63bbrevem16vtreatmentinchildrenwithseasonalallergicrhinitisandintermittentasthma
AT capassomichele bifidobacteriummixtureblongumbb536binfantism63bbrevem16vtreatmentinchildrenwithseasonalallergicrhinitisandintermittentasthma
AT maiellonunzia bifidobacteriummixtureblongumbb536binfantism63bbrevem16vtreatmentinchildrenwithseasonalallergicrhinitisandintermittentasthma
AT decimofabio bifidobacteriummixtureblongumbb536binfantism63bbrevem16vtreatmentinchildrenwithseasonalallergicrhinitisandintermittentasthma
AT ciprandigiorgio bifidobacteriummixtureblongumbb536binfantism63bbrevem16vtreatmentinchildrenwithseasonalallergicrhinitisandintermittentasthma